Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

What Were the Results of the Phase 3 EMERALD Trial?

SEP 25, 2017 | CONTAGION® EDITORIAL STAFF


Magda Opsomer, MD, director, clinical Leader, Infectious Diseases and Vaccines, Janssen Pharmaceutical Companies, Belgium, provides some insight into the phase 3 EMERALD trial regarding individuals infected with HIV who are suppressed on their treatment. Dr. Opsomer shares that the results are favorable and the fact that it is a single-tablet regimen may work to improve adherence to treatment. Dr. Opsomer also shares some of the “high points” of the study. Recently, Janssen Research & Development submitted a new drug application to the US Food and Drug Administration for the new darunavir-based regimen.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.